Expertise in
18
conditions

Dr. Auris O. Huen

Dermatology
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life Sciences Pla, 
Houston, TX 
Offers Telehealth
Expertise in
18
conditions
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life Sciences Pla, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Auris Huen is a Dermatologist in Houston, Texas. Dr. Huen is highly rated in 18 conditions, according to our data. Her top areas of expertise are Mycosis Fungoides, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Lymphomatoid Papulosis, and Thymectomy.

Her clinical research consists of co-authoring 53 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life Sciences Pla, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)
Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: SGN-35
Study Phase: Phase 2
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma
A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma
Enrollment Status: Completed
Publish Date: January 13, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

53 Total Publications

The Great Mimicker: Forgotten but not Gone.
The Great Mimicker: Forgotten but not Gone.
Journal: American journal of medicine open
Published: December 15, 2024
Similar Doctors
Expertise in
10
conditions
Dr. Michael R. Migden
Dermatology
Expertise in
10
conditions
Dr. Michael R. Migden
Dermatology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life Sciences Pla, 
Houston, TX 
 (0.1 mi)
713-592-5433
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Migden is a Dermatologist in Houston, Texas. Dr. Migden is highly rated in 10 conditions, according to our data. His top areas of expertise are Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Melanoma, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Migden is currently accepting new patients.

Expertise in
14
conditions
Dr. Adelaide A. Hebert
Dermatology
Expertise in
14
conditions
Dr. Adelaide A. Hebert
Dermatology

UT Physicians

6410 Fannin St, 
Houston, TX 
 (0.8 mi)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Adelaide Hebert is a Dermatologist in Houston, Texas. Dr. Hebert is highly rated in 14 conditions, according to our data. Her top areas of expertise are Acne, Atopic Dermatitis, Molluscum Contagiosum, and Impetigo. Dr. Hebert is currently accepting new patients.

Stephen K. Tyring
Expertise in
29
conditions
Dr. Stephen K. Tyring
Dermatology
Expertise in
29
conditions
Dr. Stephen K. Tyring
Dermatology

Dermatological Association Of Texas PLLC

451 N Texas Ave, 
Webster, TX 
 (20.6 mi)
281-333-3376
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephen Tyring is a Dermatologist in Webster, Texas. Dr. Tyring is highly rated in 29 conditions, according to our data. His top areas of expertise are Shingles, Plaque Psoriasis, Psoriasis, and Warts. Dr. Tyring is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Huen's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 67 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile